John S Madej New President at Web Industries

John S Madej will report to Mark Pihl, who will continue in his current role as chief executive officer.

Madej joins Web Industries from Hollingsworth & Vose (H&V), where he most recently served as chief operating officer and previously as chief financial officer. He joined H&V in 2009 as vice president and general manager of the Energy and Industrial Systems Business Unit. He was also the division president of the Engine and Industrial Filtration Division.

For more than 24 years, Madej served in a variety of leadership roles at General Electric (GE). He was president and CEO of Exatec LLC, a GE-Bayer joint venture. He also served as a product general manager based in Tokyo, Japan, for four years. Preceding his overseas assignment for GE, Madej held foundational positions in sales and market team leadership in multiple industry segments ranging from business equipment to automotive. Madej earned a bachelor of science degree in electrical engineering from Union College.

“John is a gifted leader and strategist. His experience as a global industrial executive and ability to successfully scale and grow businesses profitably will help us position the company for significant growth ahead,” says Pihl. “John is a leader who puts people first and has a strong commitment to teamwork and continuous improvement. As Web continues to evolve in our strategic markets and expand internationally, look for John to apply his experience to focus our market teams on providing exceptional value to customers by building strong partnerships and driving innovation through operational excellence and next-generation technology.”

“I am excited to join the Web Industries team and work together to continue to develop the company and expand the growing business,” says Madej. “Working closely with its customers, Web Industries has a successful track record of global growth across diverse markets. I look forward to collaborating with the team, expanding the company’s capabilities and delivering improved productivity and performance for our customers into the future.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”